| Schedule Of Segment Reporting Information |
| |
|
Consumer
Products Segment |
|
|
Specialty
Pharmaceutical Segment |
|
|
Consolidated
Totals |
|
| Years Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| December 31, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales,
net |
|
$ |
20,679,239 |
|
|
$ |
– |
|
|
$ |
20,679,239 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross profit |
|
$ |
14,488,664 |
|
|
$ |
– |
|
|
$ |
14,488,664 |
|
| Loss on extinguishment of debt |
|
|
(188,822 |
) |
|
|
– |
|
|
|
(188,822 |
) |
| Gain on change in derivative liability |
|
|
248,875 |
|
|
|
– |
|
|
|
248,875 |
|
| Royalty buy-out |
|
|
(2,432,000 |
) |
|
|
– |
|
|
|
(2,432,000 |
) |
| Selling, general and administrative |
|
|
(16,016,615 |
) |
|
|
(235,761 |
) |
|
|
(16,252,376 |
) |
| Research and development |
|
|
(251,134 |
) |
|
|
(473,195 |
) |
|
|
(724,329 |
) |
| Operating loss |
|
$ |
(4,151,032 |
) |
|
$ |
(708,956 |
) |
|
$ |
(4,859,988 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| December 31, 2016: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
11,060,636 |
|
|
$ |
– |
|
|
$ |
11,060,636 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Gross profit |
|
$ |
6,997,635 |
|
|
$ |
– |
|
|
$ |
6,997,635 |
|
| Gain on collection of related party notes receivable |
|
|
379,486 |
|
|
|
– |
|
|
|
379,486 |
|
| Gain on change of derivative liability |
|
|
147,200 |
|
|
|
– |
|
|
|
147,200 |
|
| Impairment of inventory |
|
|
(3,562,459 |
) |
|
|
– |
|
|
|
(3,562,459 |
) |
| Impairment of PhytoSPHERE goodwill and intangible
assets |
|
|
(2,746,512 |
) |
|
|
– |
|
|
|
(2,746,512 |
) |
| Selling, general and administrative |
|
|
(12,741,211 |
) |
|
|
(388,739 |
) |
|
|
(13,129,950 |
) |
| Research and development |
|
|
(834,963 |
) |
|
|
(324,046 |
) |
|
|
(1,159,009 |
) |
| Operating loss |
|
$ |
(12,360,824 |
) |
|
$ |
(712,785 |
) |
|
$ |
(13,073,609 |
) |
|